Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20838393 | 1.00 | HTR2A (0.40) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL20838394 | 1.00 | HTR2A (0.40) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL6950343 | 0.79 | CA1 (0.41) | SLC6A4SLC6A2SLC6A3KCNH2CYP3A4 | |
| SCHEMBL19329845 | 0.79 | SLC6A4 (0.46) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL19346524 | 0.79 | SLC6A4 (0.46) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL11633696 | 0.79 | TAAR1 (0.54) | HTR2ASLC6A4SLC6A2SLC6A3TAAR1 | |
| SCHEMBL20838367 | 0.77 | SLC6A2 (0.39) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL19346592 | 0.77 | SLC6A2 (0.39) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL29881279 | 0.77 | SLC6A2 (0.39) | HTR2ASLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL20838377 | 0.75 | CES2 (0.39) | SLC6A4SLC6A2SLC6A3CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | NOVARTIS AG (CH) | 2022-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453677-B2 | Tricyclic compounds useful to treat orthomyxovirus infections | ZC3HAV1, OTC, THOP1 | HTR2A 4648/4885SLC6A4 3714/4885SLC6A2 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.